Roche’s Cancer Drug T-DM1 Shows Promise in Study

Roche Holding AG’s experimental cancer drug T-DM1 is more effective than older therapies, with substantially fewer side-effects in breast cancer, giving the Swiss drugmaker’s pipeline a much needed boost.
CNBC